Endoscopic Ultrasonography of the Pancreas



Endoscopic Ultrasonography of the Pancreas


Anand R. Gupte

Disaya Chavalitdhamrong

Mihir S. Wagh





BACKGROUND



  • EUS was first introduced by Dr. Eugene DiMagno in the 1980s. Initial echoendoscopes were radial, which scan perpendicular to the axis of the endoscope and provide 360-degree images similar to computed tomography (CT). In 1991, a convex linear-array echoendoscope was introduced. These linear echoendoscopes scan parallel to the longitudinal axis of the endoscope and enable fine needle aspiration (FNA) and various therapeutic interventions.


  • Over the past two decades, EUS has evolved to become an indispensible tool for the evaluation of the pancreas. EUS is useful for the detection, diagnosis, staging, and treatment of multiple pancreatic disorders including solid pancreatic masses, pancreatic cystic lesions, and acute and chronic pancreatitis.


  • Currently, two types of echoendoscopes are available: radial sector and linear-array transducers. Radial and linear EUS provides high-resolution images of the gut lumen, the adjacent organs, the lymph nodes, and the vascular structures. They are also equipped with color Doppler, which allows for accurate identification of vascular structures and aids in vascular staging of pancreatic tumors.


  • EUS is a safe procedure. Complications are rare and typically related to therapeutic efforts. EUS-FNA complications include bleeding (0% to 1.3%), perforation (0% to 0.4%), infection (0.3%), and pancreatitis (1% to 2%).1,2 The risk of bacteremia is low, and prophylactic antibiotics are not recommended except prior to EUS-guided FNA of pancreatic cystic lesions. The risk of tumor seeding is significantly lower as compared to percutaneous approaches with only four case reports so far.2


PANCREATIC DISORDERS AND ENDOSCOPIC ULTRASONOGRAPHY FINDINGS



  • Pancreatic tumors typically appear as irregularly shaped hypoechoic or heterogeneous areas within the normal echo texture of the pancreas. In cases of pancreatic cancer, tumor extension into the adjacent vasculature (portal; splenic and superior mesenteric veins; and celiac, splenic, and superior mesenteric arteries), the common bile duct, and the duodenum can be identified. Additionally, ascites, celiac and peripancreatic lymph nodes, and metastatic disease to the liver can be seen.


  • Pancreatic cysts are divided into nonneoplastic and neoplastic cysts. EUS findings should be interpreted in the context of the clinical impression, morphologic EUS criteria, and results of the cystic fluid analysis to determine the origin of the cyst and guidance of further management. Morphologic features associated with an increased risk for malignancy are an irregular or thickened cyst wall, the presence of mural nodules or a solid mass within the cyst, a cyst size over 3 cm, or an increase in cyst size during follow-up.


  • EUS can help identify causes of pancreatitis, including gallbladder and bile duct stones and sludge (microlithiasis), pancreatic duct stones, pancreatic cysts (pseudocysts and cystic neoplasms), ampullary neoplasms, pancreas divisum, changes of chronic pancreatitis, and pancreatic masses.


  • EUS is sensitive to subtle changes associated with chronic pancreatitis. It shows fine parenchymal details such as early fibrosis, calcifications, and pancreatic ductal changes. The diagnosis of chronic pancreatitis by EUS depends on the presence or absence of multiple EUS criteria of chronic pancreatitis (Rosemont classification),3 which includes parenchymal features of echogenic foci, focal regions of increased echogenicity (strands), lobularity, cyst formation, and ductal EUS features (increased echogenicity of the main pancreatic duct wall, main pancreatic duct calculi, irregular contour of the main pancreatic duct, dilation of the main pancreatic duct, and side branch dilation).


OTHER DIAGNOSTIC STUDIES



  • In the 1980s, EUS was developed to overcome the limitations of transabdominal ultrasonography (US) and CT scan imaging of the pancreas.


  • EUS provides high-resolution images of the pancreatic duct, as well as the parenchyma, and complements the ductal images seen in endoscopic retrograde cholangiopancreatography (ERCP).


  • EUS is considered one of the most sensitive imaging modalities to detect pancreatic tumors and has the additional advantage of acquiring tissue samples by FNA with linear endosonography. The sensitivity of EUS ranges from 93% to 100%, whereas for CT, it ranges from 53% to 92%.4


  • Compared to US- or CT-guided FNA, EUS-FNA has been proven to be the safest technique with comparable accuracy (76% of EUS vs. 81% of US/CT).5 The sensitivity of EUSFNA for diagnosing pancreatic cancer is greater than 90% with a specificity of greater than 95%.4


MANAGEMENT


Preoperative Planning



  • A recent complete blood count, basic electrolytes, and coagulation studies are indicated prior to EUS. The patient
    should hold anticoagulants and antiplatelet agents or use bridge therapy with heparin before EUS-guided FNA.


  • Patients are normally instructed to fast after midnight, the night before the procedure.


  • Prophylactic antibiotics are recommended only for EUSguided FNA of cystic lesions.6


  • The procedure is generally performed under conscious sedation or monitored anesthesia care based on presence of associated medical comorbidities.


Positioning



  • EUS of the pancreas is usually performed with the patient in the left lateral decubitus position, similar to that for performing an esophagogastroduodenoscopy (EGD).


  • If drainage of pancreatic fluid collections is planned, a prone position is preferred to facilitate better fluoroscopic visualization without interference from bony structures; this positioning also fosters the concomitant performance of ERCP if indicated.

Jul 24, 2016 | Posted by in GENERAL SURGERY | Comments Off on Endoscopic Ultrasonography of the Pancreas

Full access? Get Clinical Tree

Get Clinical Tree app for offline access